You are here

Gamma-ketoaldehyde scavengers for alcoholic liver disease

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AA023715-01
Agency Tracking Number: R43AA023715
Amount: $151,587.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAAA
Solicitation Number: PA14-071
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2711 S LOOP DR, STE 4400
AMES, IA 50010-8656
United States
DUNS: 937516276
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (515) 296-9916
Business Contact
Phone: (515) 296-9916
Research Institution

DESCRIPTION (provided by applicant): Chronic alcohol overconsumption is the third largest risk factor for disease burden worldwide and is a frequent comorbidity of liver disease and cancer. While abstinence is a cornerstone of treatment, there is considerable interest in identifying other therapeutic interventions for alcoholic liver disease (ALD). Such advances are complicated by an incomplete understanding of the relationship between alcohol-specific metabolic responses and liver pathophysiology. The induction of a pro-inflammatory state, hallmark of ALD, appears to depend upon the unfavorable interplay among reactive oxygen species (ROS), protein adduct formation, and both the innate and adaptive immune responses. In this SBIR Phase I project, we hypothesize that the formation of highly reactive compounds, termed ?-ketoaldehydes (?-KA), formed primarily by non-enzymatic free radical catalyzed lipid peroxidation and secondarily by cyclooxygenases (COX) activity, is crucial for ethanol-induced liver injury.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government